Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.
about
From docking false-positive to active anti-HIV agent.Search for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoringFactors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patientsPolarization Effects for Hydrogen-Bonded Complexes of Substituted Phenols with Water and Chloride IonCharacterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1Identification of HIV inhibitors guided by free energy perturbation calculations.C-2-aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors.DNA polymerases as therapeutic targetsEfficient drug lead discovery and optimization.Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection.From base pair to bedside: molecular simulation and the translation of genomics to personalized medicine.Arylsulfone-based HIV-1 non-nucleoside reverse transcriptase inhibitors.Computer-aided discovery of anti-HIV agents.TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.Novel theoretically designed HIV-1 non-nucleoside reverse transcriptase inhibitors derived from nevirapine.Bifunctional inhibition of human immunodeficiency virus type 1 reverse transcriptase: mechanism and proof-of-concept as a novel therapeutic design strategy.Efficacy and resistance of recently developed non-nucleoside reverse transcriptase inhibitors for HIV-1
P2860
Q33301713-82FF6830-636E-42BC-9B20-F26B82803EFAQ33303221-8CAFA098-3ED3-4EB2-89C3-97C8DFEAD33CQ33558937-D82C1264-67C3-432E-A490-A5AA49EB8C2EQ34373691-2568D2E8-5CD5-4BB1-A2C7-5F7BF79054A6Q34529310-BAA7F550-DEAD-4784-A61A-C55D97E26CAFQ35557235-E4C81759-EF19-4544-B4BF-C58140B06A81Q36708826-4F0DB233-C8A5-4023-84CD-DDF581467584Q37091525-112C78EA-D56B-4F82-8B1E-E36F2DAEE1EBQ37216862-5C2865CE-E8C9-4D4E-A014-A02C990D8CBCQ37307959-07533222-9F55-4FA1-BC8D-3710AE11AD54Q37405054-D60AD294-61BA-46F3-869A-F915ED9AFC2EQ38035239-C2CC2987-1FC5-4F7B-9B28-4EA1C4D89C93Q38164839-C5EDEFA2-EC7E-4E4C-82DD-77CB6F5E36A1Q38916780-BB26BFBF-FFB1-4D65-A438-E3A5DF0A8C15Q42033549-43169BF8-507F-4CA3-9AA1-2F95B46FA3EBQ42186848-3DD7CAFB-D0F7-4238-86A4-C9CAF67C81B3Q42537068-CA67370E-D4C9-4A92-946A-ED0FD29D8C69Q58388963-286CF5B9-E205-4065-9F64-9C2BF3BB3976
P2860
Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Validation of a model for the ...... onnucleoside inhibitor TMC125.
@en
Validation of a model for the ...... onnucleoside inhibitor TMC125.
@nl
type
label
Validation of a model for the ...... onnucleoside inhibitor TMC125.
@en
Validation of a model for the ...... onnucleoside inhibitor TMC125.
@nl
prefLabel
Validation of a model for the ...... onnucleoside inhibitor TMC125.
@en
Validation of a model for the ...... onnucleoside inhibitor TMC125.
@nl
P356
P1476
Validation of a model for the ...... onnucleoside inhibitor TMC125.
@en
P2093
Julian Tirado-Rives
Marina Udier-Blagović
P304
P356
10.1021/JA034308C
P407
P577
2003-05-01T00:00:00Z